BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 33765753)

  • 1. Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening.
    Poljak M; Cuschieri K; Waheed DE; Baay M; Vorsters A
    Acta Dermatovenerol Alp Pannonica Adriat; 2021 Mar; 30(1):21-26. PubMed ID: 33765753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating a community-based cervical cancer screening strategy in Western Kenya: a descriptive study.
    Swanson M; Ibrahim S; Blat C; Oketch S; Olwanda E; Maloba M; Huchko MJ
    BMC Womens Health; 2018 Jul; 18(1):116. PubMed ID: 29970063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knowledge, attitudes, and practices of cervical Cancer screening among HIV-positive and HIV-negative women participating in human papillomavirus screening in rural Zimbabwe.
    Fitzpatrick M; Pathipati MP; McCarty K; Rosenthal A; Katzenstein D; Chirenje ZM; Pinsky B
    BMC Womens Health; 2020 Jul; 20(1):153. PubMed ID: 32711530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low rates of HPV vaccination and cervical cancer screening: Challenges and opportunities in the context of the COVID-19 pandemic.
    Smith DL; Perkins RB
    Prev Med; 2022 Jun; 159():107070. PubMed ID: 35461955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunities and challenges for introducing HPV testing for cervical cancer screening in sub-Saharan Africa.
    Tsu VD; Njama-Meya D; Lim J; Murray M; de Sanjose S
    Prev Med; 2018 Sep; 114():205-208. PubMed ID: 30031013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated cervical cancer screening in Mayuge District Uganda (ASPIRE Mayuge): a pragmatic sequential cluster randomized trial protocol.
    Nakisige C; Trawin J; Mitchell-Foster S; Payne BA; Rawat A; Mithani N; Amuge C; Pedersen H; Orem J; Smith L; Ogilvie G
    BMC Public Health; 2020 Jan; 20(1):142. PubMed ID: 32005202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of COVID-19 on cervical cancer screening: Challenges and opportunities to improving resilience and reduce disparities.
    Wentzensen N; Clarke MA; Perkins RB
    Prev Med; 2021 Oct; 151():106596. PubMed ID: 34217415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: preliminary results of a randomised controlled trial.
    Moses E; Pedersen HN; Mitchell SM; Sekikubo M; Mwesigwa D; Singer J; Biryabarema C; Byamugisha JK; Money DM; Ogilvie GS
    Trop Med Int Health; 2015 Oct; 20(10):1355-67. PubMed ID: 26031572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Cervical Cancer Screening Among Infrequently Screened Women Completing Human Papillomavirus Self-Collection: My Body My Test-1.
    Lea CS; Perez-Heydrich C; Des Marais AC; Richman AR; Barclay L; Brewer NT; Smith JS
    J Womens Health (Larchmt); 2019 Aug; 28(8):1094-1104. PubMed ID: 30874477
    [No Abstract]   [Full Text] [Related]  

  • 10. Uptake and correlates of cervical cancer screening among women attending a community-based multi-disease health campaign in Kenya.
    Choi Y; Ibrahim S; Park LP; Cohen CR; Bukusi EA; Huchko MJ
    BMC Womens Health; 2022 Apr; 22(1):122. PubMed ID: 35436908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
    Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
    Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Worldwide use of HPV self-sampling for cervical cancer screening.
    Serrano B; Ibáñez R; Robles C; Peremiquel-Trillas P; de Sanjosé S; Bruni L
    Prev Med; 2022 Jan; 154():106900. PubMed ID: 34861338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
    Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
    Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
    Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
    Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High risk HPV infection prevalence and associated cofactors: a population-based study in female ISSSTE beneficiaries attending the HPV screening and early detection of cervical cancer program.
    Torres-Poveda K; Ruiz-Fraga I; Madrid-Marina V; Chavez M; Richardson V
    BMC Cancer; 2019 Dec; 19(1):1205. PubMed ID: 31823749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake of Cervical Cancer Screening in Ethiopia by Self-Sampling HPV DNA Compared to Visual Inspection with Acetic Acid: A Cluster Randomized Trial.
    Gizaw M; Teka B; Ruddies F; Abebe T; Kaufmann AM; Worku A; Wienke A; Jemal A; Addissie A; Kantelhardt EJ
    Cancer Prev Res (Phila); 2019 Sep; 12(9):609-616. PubMed ID: 31337647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis.
    Smith MA; Burger EA; Castanon A; de Kok IMCM; Hanley SJB; Rebolj M; Hall MT; Jansen EEL; Killen J; O'Farrell X; Kim JJ; Canfell K
    Prev Med; 2021 Oct; 151():106623. PubMed ID: 34029578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system.
    Frayle H; Gori S; Rizzi M; Graziani BN; Vian E; Giorgi Rossi P; Del Mistro A
    BMC Womens Health; 2019 Mar; 19(1):47. PubMed ID: 30909894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV-based cervical cancer screening in Nicaragua: from testing to treatment.
    Holme F; Maldonado F; Martinez-Granera OB; Rodriguez JM; Almendarez J; Slavkovsky R; Bansil P; Thomson KA; Jeronimo J; de Sanjose S
    BMC Public Health; 2020 Apr; 20(1):495. PubMed ID: 32295562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.